Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Vagner

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Journal of Medicinal Chemistry|February 13, 2008
A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonistsTakashi Yamamoto, Padma Nair, Josef Vagner, et al.
Molecular Pharmaceutics|June 15, 2013
In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanomaNarges K Tafreshi, Ariosto Silva, Veronica C Estrella, et al.
Molecular Pharmaceutics|December 30, 2015
Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5Amanda Shanks Huynh, Veronica Estrella, Valerie E Stark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2011
Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probesNarges K Tafreshi, Marilyn M Bui, Kellsey Bishop, et al.
Journal of Medicinal Chemistry|July 19, 2013
Development and in vivo quantitative magnetic resonance imaging of polymer micelles targeted to the melanocortin 1 receptorNatalie M Barkey, Christian Preihs, Heather H Cornnell, et al.
Cancer Research Communications|September 25, 2024
Intraoperative Guidance of Pancreatic Cancer Resection Using a Toll-like Receptor 2-Targeted Fluorescence Molecular Imaging AgentAmanda S Huynh, Allison S Cohen, Michael Doligalski, et al.
JCI Insight|May 1, 2020
The cellular basis of protease-activated receptor 2-evoked mechanical and affective painShayne N Hassler, Moeno Kume, Juliet M Mwirigi, et al.
Bioorganic & Medicinal Chemistry|July 30, 2013
Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptorsRamesh Alleti, Josef Vagner, Dilani Chathurika Dehigaspitiya, et al.
Biopolymers|July 28, 2007
Opioid and melanocortin receptors: do they have overlapping pharmacophores?Yeon Sun Lee, Richard S Agnes, James P Cain, et al.
The Journal of Pain|January 11, 2021
A Role for Protease Activated Receptor Type 3 (PAR3) in Nociception Demonstrated Through Development of a Novel Peptide AgonistJuliet Mwirigi, Moeno Kume, Shayne N Hassler, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Journal of Medicinal Chemistry|February 13, 2008
A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonistsTakashi Yamamoto, Padma Nair, Josef Vagner, et al.
Molecular Pharmaceutics|June 15, 2013
In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanomaNarges K Tafreshi, Ariosto Silva, Veronica C Estrella, et al.
Molecular Pharmaceutics|December 30, 2015
Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5Amanda Shanks Huynh, Veronica Estrella, Valerie E Stark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2011
Noninvasive detection of breast cancer lymph node metastasis using carbonic anhydrases IX and XII targeted imaging probesNarges K Tafreshi, Marilyn M Bui, Kellsey Bishop, et al.
Journal of Medicinal Chemistry|July 19, 2013
Development and in vivo quantitative magnetic resonance imaging of polymer micelles targeted to the melanocortin 1 receptorNatalie M Barkey, Christian Preihs, Heather H Cornnell, et al.
Cancer Research Communications|September 25, 2024
Intraoperative Guidance of Pancreatic Cancer Resection Using a Toll-like Receptor 2-Targeted Fluorescence Molecular Imaging AgentAmanda S Huynh, Allison S Cohen, Michael Doligalski, et al.
JCI Insight|May 1, 2020
The cellular basis of protease-activated receptor 2-evoked mechanical and affective painShayne N Hassler, Moeno Kume, Juliet M Mwirigi, et al.
Bioorganic & Medicinal Chemistry|July 30, 2013
Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptorsRamesh Alleti, Josef Vagner, Dilani Chathurika Dehigaspitiya, et al.
Biopolymers|July 28, 2007
Opioid and melanocortin receptors: do they have overlapping pharmacophores?Yeon Sun Lee, Richard S Agnes, James P Cain, et al.
The Journal of Pain|January 11, 2021
A Role for Protease Activated Receptor Type 3 (PAR3) in Nociception Demonstrated Through Development of a Novel Peptide AgonistJuliet Mwirigi, Moeno Kume, Shayne N Hassler, et al.
Pageof 8